ASTRO updates guideline on radiation therapy for pancreatic cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

An updated clinical guideline from the American Society for Radiation Oncology provides evidence-based recommendations on the use of radiation therapy to treat adult patients with pancreatic cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Rasonque (daraxonrasib) consistently provided an overall survival benefit compared with chemotherapy across all evaluated RAS genotype subgroups among patients with previously treated metastatic pancreatic adenocarcinoma, including those with no identified tumor RAS mutation, according to exploratory subgroup analyses from the phase III RASolute 302 trial.
Camupepimut (ELI-002 7P) demonstrated consistent and favorable treatment-effect trends in patients with and without detectable baseline ctDNA and in patients without prior radiation across multiple pre-specified analyses, according to the results of a randomized phase II study of patients with resected pancreatic ductal adenocarcinoma called AMPLIFY-7P. 
A multi-center clinical trial led by researchers at The University of Texas MD Anderson Cancer Center has found that implanting collagen tiles during brain surgery to deliver targeted radiation therapy dramatically improved tumor control, lowered the risk of recurrence, and improved overall survival compared to current standard of care for patients with newly diagnosed brain metastases in need of surgical resection.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login